Rehmann Capital Advisory Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rehmann Capital Advisory Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280K	Buy	954 +73	+8%	+$20.7K	0.01%	585
2026 Q1	$246K	Buy	881 +221	+33%	+$63.6K	0.01%	594
2025 Q4	$201K	Buy	+660	New	+$206K	0.01%	647
2019 Q3	–	Sell	-134	Closed	-$41.9K	–	1712
2019 Q2	$41.9K	Buy	134 +10	+8%	+$2.99K	0.01%	905
2019 Q1	$37.9K	Sell	124 -7	-5%	-$1.89K	0.01%	905
2018 Q4	$30.4K	Buy	131 +5	+4%	+$1.34K	﹤0.01%	741
2018 Q3	$39.4K	Sell	126 -3	-2%	-$931	0.01%	891
2018 Q2	$37.2K	Buy	129 +9	+8%	+$2.48K	0.01%	885
2018 Q1	$30K	Buy	+120	New	+$30.6K	﹤0.01%	930

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Rehmann Capital Advisory Group's BIO Position: Q2 2026 in Review

Rehmann Capital Advisory Group increased its Bio-Rad Laboratories Class A (BIO) stake by 8.3% in Q2 2026, buying an estimated $20.7K and bringing the position to 954 shares worth $280K. The position accounts for 0.01% of the portfolio, ranked #585.

Rehmann Capital Advisory Group first reported a position in BIO in Q1 2018 and has held it in 9 quarters since. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Rehmann Capital Advisory Group held 954 shares of Bio-Rad Laboratories Class A worth $280K as of Q2 2026.
Rehmann Capital Advisory Group bought 73 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $20.7K.
Bio-Rad Laboratories Class A made up 0.01% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #585 holding.
Rehmann Capital Advisory Group first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and has held it in 9 quarters since.
399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.